Screener
Madrigal Pharmaceuticals, Inc. MDGL Total Cost of Revenue
Discontinued — last reported Q4 '24
Total Cost of Revenue at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Madrigal Pharmaceuticals, Inc.’s 10-K, filed February 26, 2025.
- Filed
- Feb 26, 2025
- Fiscal year
- FY2024
- Accession
- 0001628280-25-007980
| Line item | Year Ended December 31, 2024 | Year Ended December 31, 2023 | Year Ended December 31, 2022 |
|---|---|---|---|
| Revenues: | |||
| Product revenue, net | $180,133 | — | — |
| Operating expenses: | |||
| Cost of sales | 6,233 | — | — |
| Research and development | 236,718 | 272,350 | 245,441 |
| Selling, general and administrative | 435,057 | 108,146 | 48,130 |
| Total operating expenses | 678,008 | 380,496 | 293,571 |
| Loss from operations | (497,875) | (380,496) | (293,571) |
Item 16. Form 10-K Summary.
FAQ
- What is Madrigal Pharmaceuticals, Inc.'s total cost of revenue?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported total cost of revenue of $1.56M in Q4 2024.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.
Ask your AI about Madrigal Pharmaceuticals, Inc.'s total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude